NCT07044921View on ClinicalTrials.gov

Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Irinotecan Liposomes (II)+Cetuximab+Bevacizumabl

"Irinotecan Liposomes (II) injection：Intravenous infusion, 60 mg/m2, Day 1, Q2W. The recommended initial dosage of irinotecan liposomes (II) for patients with the UGT1A1 \* 28/\* 6 homozygous mutation is 47.1 mg/m2.~Cetuximab injection：Intravenous infusion, 500 mg/m2, Day 1, Q2W. Bevacizumabl: Intravenous infusion, 5mg/kg, Day 1, Q2W."

Trial Locations (1)

Unknown

RECRUITING

Chinese PLA General Hospital, Beijing,, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER